InvestorsHub Logo
Followers 5
Posts 72
Boards Moderated 0
Alias Born 01/14/2011

Re: cjgaddy post# 84280

Saturday, 07/21/2012 9:56:50 AM

Saturday, July 21, 2012 9:56:50 AM

Post# of 345789
From Joe Shan's commentary on the 7/16 conference call:

It is extremely encouraging that the MOS then, and even to date, has not yet been reached in either of the bavituximab-containing arms, with some patients continuing to receive bavituximab maintenance. This trial will remain open to collect survival follow-up until at least a median number.........

Any thoughts on "Bavituximab maintenance"? Dosage, frequency, patient criteria? I haven't heard much about this possible use for Bavi. Would certain patient populations be put on a maintenance dose of Bavi to prrevent further progression of their illness?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News